TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Lowered by Wall Street Zen

TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

TLSI has been the subject of several other reports. Lake Street Capital decreased their price objective on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Friday, August 7th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.50.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock opened at $5.27 on Friday. The company has a market capitalization of $324.53 million, a P/E ratio of -4.05 and a beta of 0.43. The company has a debt-to-equity ratio of 5.05, a quick ratio of 4.97 and a current ratio of 5.35. TriSalus Life Sciences has a fifty-two week low of $2.20 and a fifty-two week high of $7.95. The stock has a 50-day simple moving average of $4.39 and a 200-day simple moving average of $4.30.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.16). The firm had revenue of $11.41 million for the quarter, compared to analysts’ expectations of $10.27 million.

Institutional Investors Weigh In On TriSalus Life Sciences

Several hedge funds have recently modified their holdings of TLSI. Cura Wealth Advisors LLC purchased a new position in TriSalus Life Sciences in the 2nd quarter valued at $36,000. JPMorgan Chase & Co. raised its position in TriSalus Life Sciences by 35,804.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after buying an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in TriSalus Life Sciences during the 2nd quarter worth $47,000. Invesco Ltd. acquired a new stake in shares of TriSalus Life Sciences in the 4th quarter worth $72,000. Finally, Abel Hall LLC acquired a new stake in shares of TriSalus Life Sciences in the 4th quarter worth $73,000. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.